Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

dc.authorid0000-0001-7566-1063
dc.authorid0000-0002-7685-2766
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKınıkoğlu, Oğuzcan
dc.contributor.authorHelvacı Yılmaz, Nesrin
dc.contributor.authorBilici, Ahmet Erkan
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorŞeker, Mesut Metin
dc.contributor.authorÇakır, Tansel
dc.contributor.authorYıldız, Özcan
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:47Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:47Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyoloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractParaneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus–myoclonus–ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%–25% of breast cancer and is associated with poor prognosis. There are a few reports of paraneoplastic neurological syndrome associated with HER2-positive breast cancer in the literature, of which most are anti-Yo-associated paraneoplastic neurological syndrome. We present herein the case of a female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome. Following the diagnosis of paraneoplastic syndrome, chemotherapy with dual HER2 blockade and immunomodulating treatment including intravenous immunoglobulin and oral prednisolone were administered. Although the patient was negative for serum anti-Ri antibodies, there was partial clinical improvement and her neurological deficit persisted. To our knowledge, this is the first case report of female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome and treated with dual HER2 blockade.
dc.identifier.citationÖlmez, Ö. F., Kınıkoğlu, O., Helvacı Yılmaz, N., Bilici, A. E., Çubukçu, E., Şeker, M. M. … Hamdard, J. (2019). Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade. Journal of Oncology Pharmacy Practice, 25(6), 1526-1530. https://dx.doi.org/10.1177/1078155218792672
dc.identifier.doi10.1177/1078155218792672
dc.identifier.endpage1530
dc.identifier.issn1078-1552
dc.identifier.issue6
dc.identifier.scopusqualityQ3
dc.identifier.startpage1526
dc.identifier.urihttps://hdl.handle.net/20.500.12511/945
dc.identifier.urihttps://dx.doi.org/10.1177/1078155218792672
dc.identifier.volume25
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBreast Cancer
dc.subjectHER2 Blockade
dc.subjectOpsoclonus–Myoclonus Syndrome
dc.subjectParaneoplastic Neurological Syndrome
dc.titleAnti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Ölmez, Ömer Fatih.pdf
Boyut:
621.98 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text